Our studies and the work of other groups have strongly suggested that re-activation of the p53 signaling pathway is strongly implicated in chemotherapy- and endocrine therapy-resistant breast cancers, especially in the most prevalent breast cancer sub-type (ERα+/p53+) [93,98]. The gene discussed is ESR1; the disease is breast carcinoma.